Stock Forecast Chart
Stock Price Prediction Summary
Forecast Score Based on 2 Weeks
Based on our forecast, the price of COAG will decline by -7.11% over the next 2 Weeks and hit $37.05 by Thursday, September 24, 2026. In that time frame, COAG's share price is expected to range between $34.49 and $39.48.
BearishAverageBullish| Date | Predicted Lower | Predicted | Predicted Upper |
|---|---|---|---|
| Sep 24, 2026 | 34.49 | 37.05 | 39.48 |
| Sep 23, 2026 | 35.38 | 37.78 | 40.26 |
| Sep 22, 2026 | 35.20 | 37.57 | 39.93 |
| Sep 21, 2026 | 35.26 | 37.63 | 40.04 |
| Sep 18, 2026 | 36.63 | 38.85 | 41.12 |
| Sep 17, 2026 | 37.06 | 39.43 | 41.67 |
| Sep 16, 2026 | 37.66 | 40.17 | 42.55 |
| Sep 15, 2026 | 37.74 | 39.96 | 42.24 |
| Sep 14, 2026 | 37.68 | 40.02 | 42.46 |
| Sep 11, 2026 | 38.92 | 41.24 | 43.46 |
COAG shares fell -1.44% in Friday, September 11, 2026's trading session, dropping from a previous close of $39.88 to move at $39.31. The stock demonstrated notable intraday movement (see COAG's key stats for a full breakdown), fluctuating between $39.20 and $42.48, a +8.38% trading range. While recent weeks have seen some volatility, COAG has managed to secure a -20.58% drop over the past 2 weeks. The downward price movement was accompanied by increased trading volume, with approximately 433.56K shares changing hands, 4.43K more than the previous session. This amounted to $17.04M in total market activity.
Will COAG Continue Its Upward Trend?
According to analyst ratings and projections for COAG, Hemab Therapeutics Holdings, Inc. Common Stock shares are anticipated to increase by +0.45%, potentially reaching $39.48 per share by September 24, 2026. Short-term technical indicators currently suggest a neutral sentiment for COAG. For deeper insights, view our sentiment analysis on AAPL covering social and institutional perspectives. However, the stock has recorded 17 positive trading days within the past 30 sessions. Based on the COAG stock forecast, now is a good time to buy COAG stock because its current trading price is +6.10% above our predicted value, hinting at a possible undervaluation. For deeper insights, view our sentiment analysis on COAG covering social and institutional perspectives.
COAG Technical Momentum: Overbought, Oversold, or Neutral?
An analysis of Relative Strength Index (RSI) indicators provides insight into COAG's momentum. Short-term RSIs (9, 14, and 20-day figures ranging from 23.98% to 40.06%) suggest weak bearish momentum with possible fluctuation. The 50-day RSI, at 48.38%, suggests a neutral medium-term outlook. Insights into COAG's shareholder base show how institutional investors are positioning themselves during these momentum shifts
Hemab Therapeutics Common Stock Short-Term Forecasts
COAG Forecast For Next 5 Days
Our algorithm anticipates Hemab Therapeutics Common Stock (COAG) stock could hit $42.35 by Sep 18, 2026. This represents a +7.75% fall from today's price, following a - change over the past five days.
COAG Forecast For Next 30 Days
Based on analysis of market trends, the outlook for Hemab Therapeutics Holdings, Inc. Common Stock (COAG) stock over the next 30 days is largely negative. Price forecasts suggest an average target of $39.14, which would mean a -0.42% decrease from the current price of $39.31. Projections for this period range from a high of $49.25 to a low of $27.64.
COAG Forecast For Next 90 Days
Our proprietary market analysis suggests predictions for Hemab Therapeutics Common Stock's price over the next three months point to a drop. COAG stock is expected to peak at $34.50 on Sep 11, 2026 before potentially dipping to $0.00 on Dec 11, 2026. On average, COAG is likely to trade around $0.51 in the coming 90 days.
Hemab Therapeutics Common Stock Stock Forecast 2025
Based on our predictive models, Hemab Therapeutics Common Stock (COAG) is expected to trade between $0.00 and $34.50 throughout 2026. This would result in an average price of $0.42, potentially offering investors a -98.93% return from current levels.
Hemab Therapeutics Holdings, Inc. Common Stock Monthly Forecast 2026–2027
September 2026
According to our latest forecast models, Hemab Therapeutics Holdings, Inc. Common Stock (COAG) is positioned to show a strong performance in September 2026. The price is predicted to move between $0.00 and $34.50, settling at an average of $2.42. This could translate to a -93.84% loss.
October 2026
Based on current market signals, Hemab Therapeutics Holdings, Inc. Common Stock is projected to trend october 2026. We forecast a trading range from $0.00 to $0.00, with a likely average price of $0.00. Investors could expect a potential return of -100.00%.
November 2026
Our predictive algorithms indicate Hemab Therapeutics Holdings, Inc. Common Stock stock may see a shift in November 2026. The expected range spans $0.00–$0.00, with an average target of $0.00. This represents a cautious outlook and a possible loss of -100.00%.
December 2026
Analyzing established trends, Hemab Therapeutics Holdings, Inc. Common Stock looks set to move in December 2026. Projections place the stock between $0.00 and $0.00, averaging around $0.00. This suggests a -100.00% loss from current levels.
January 2027
Market indicators suggest Hemab Therapeutics Holdings, Inc. Common Stock could experience notable changes during January 2027. Prices could fluctuate within $0.00 to $0.00, with a midpoint forecast of $0.00. The stock might deliver a -100.00% loss.
February 2027
Forecasting for February 2027, models estimate that Hemab Therapeutics Holdings, Inc. Common Stock may undergo key fluctuations. If trends hold, the stock might trade between $0.00 and $0.00, averaging $0.00. This signals a cautious trajectory with potential returns around -100.00%.
March 2027
According to our latest forecast models, Hemab Therapeutics Holdings, Inc. Common Stock (COAG) is positioned to show a strong performance in March 2027. The price is predicted to move between $0.00 and $0.00, settling at an average of $0.00. This could translate to a -100.00% loss.
April 2027
Based on current market signals, Hemab Therapeutics Holdings, Inc. Common Stock is projected to trend april 2027. We forecast a trading range from $0.00 to $0.00, with a likely average price of $0.00. Investors could expect a potential return of -100.00%.
May 2027
Our predictive algorithms indicate Hemab Therapeutics Holdings, Inc. Common Stock stock may see a shift in May 2027. The expected range spans $0.00–$0.00, with an average target of $0.00. This represents a cautious outlook and a possible loss of -100.00%.
June 2027
Analyzing established trends, Hemab Therapeutics Holdings, Inc. Common Stock looks set to move in June 2027. Projections place the stock between $0.00 and $0.00, averaging around $0.00. This suggests a -100.00% loss from current levels.
July 2027
Market indicators suggest Hemab Therapeutics Holdings, Inc. Common Stock could experience notable changes during July 2027. Prices could fluctuate within $0.00 to $0.00, with a midpoint forecast of $0.00. The stock might deliver a -100.00% loss.
August 2027
Forecasting for August 2027, models estimate that Hemab Therapeutics Holdings, Inc. Common Stock may undergo key fluctuations. If trends hold, the stock might trade between $0.00 and $0.00, averaging $0.00. This signals a cautious trajectory with potential returns around -100.00%.
September 2027
According to our latest forecast models, Hemab Therapeutics Holdings, Inc. Common Stock (COAG) is positioned to show a strong performance in September 2027. The price is predicted to move between $0.00 and $0.00, settling at an average of $0.00. This could translate to a -100.00% loss.
COAG's history of dividends and stock splits also plays a role in long-term investor confidence.